Company & Sponsor Intelligence
Hoffmann-La Roche
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials2
Recruiting0
Completed0
Countries1
Therapeutic footprint
alzheimers
Indexed studies
NCT03491150An Open-Label Crenezumab Study in Participants With Alzheimer's Disease
alzheimers · United StatesPHASE3
alzheimers · United StatesPHASE3
NCT03114657A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)
alzheimers · United StatesPHASE3
alzheimers · United StatesPHASE3
NCT03443973Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)
alzheimers · United StatesPHASE3
alzheimers · United StatesPHASE3
Intelligence layer updated: 2026-06-10 02:57:56.223123+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →